UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the month of July, 2023
Commission File Number 001-39670
PURETECH HEALTH PLC
(Translation of registrant’s name into English)
6 Tide Street, Suite 400
Boston, Massachusetts 02210
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.
During the month ended July 31, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:
Date | Ordinary Shares | Volume Weighted Average Price Paid per Ordinary Share | Highest Price Paid | Lowest Price Paid | ||||
July 3, 2023 | 52,542 | 221.63p | 223.50p | 219.50p | ||||
July 4, 2023 | 50,808 | 224.50p | 226.00p | 218.00p | ||||
July 5, 2023 | 50,935 | 224.80p | 228.00p | 220.50p | ||||
July 6, 2023 | 48,119 | 222.82p | 224.50p | 221.50p | ||||
July 7, 2023 | 45,925 | 218.46p | 220.50p | 216.00p | ||||
July 10, 2023 | 49,838 | 220.49p | 221.50p | 218.00p | ||||
July 11, 2023 | 49,568 | 220.08p | 222.00p | 218.50p | ||||
July 12, 2023 | 49,535 | 222.03p | 225.50p | 219.00p | ||||
July 13, 2023 | 47,674 | 219.71p | 220.00p | 217.00p | ||||
July 14, 2023 | 49,341 | 215.62p | 218.50p | 214.50p | ||||
July 17, 2023 | 42,082 | 214.16p | 218.00p | 211.50p | ||||
July 18, 2023 | 42,100 | 212.97p | 218.00p | 210.50p | ||||
July 19, 2023 | 41,397 | 225.33p | 227.50p | 221.00p | ||||
July 20, 2023 | 20,040 | 227.11p | 227.50p | 224.50p | ||||
July 21, 2023 | 43,256 | 229.62p | 230.00p | 227.00p |
July 24, 2023 | 42,666 | 227.86p | 232.00p | 224.50p | ||||
July 25, 2023 | 35,701 | 225.57p | 227.50p | 219.50p | ||||
July 26, 2023 | 37,881 | 228.14p | 231.00p | 226.00p | ||||
July 27, 2023 | 34,923 | 227.91p | 230.50p | 226.00p | ||||
July 28, 2023 | 37,075 | 228.79p | 230.00p | 226.00p | ||||
July 31, 2023 | 34,963 | 226.31p | 229.50p | 222.50p |
During the month ended July 31, 2023, the Company repurchased an aggregate of 906,369 Ordinary Shares. As of July 31, 2023, the Company’s issued share capital was 289,468,159 shares, 13,409,665 of which were held in treasury, resulting in total voting rights in the Company of 276,058,494 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:
July 3, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4823588.html
July 4, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4825010.html
July 5, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4826362.html
July 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4827960.html
July 7, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4829449.html
July 10, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4830934.html
July 11, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4832444.html
July 12, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4833862.html
July 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4835234.html
July 14, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4836731.html
July 18, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4839640.html
July 19, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4841104.html
July 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4842539.html
July 21, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4843990.html
July 24, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4845558.html
July 25, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4847060.html
July 26, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4848529.html
July 27, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4850197.html
July 28, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4851670.html
July 31, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4853443.html
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PURETECH HEALTH PLC | ||||||
| Date: August 2, 2023 | By: | /s/ Daphne Zohar | ||||
| Name: | Daphne Zohar | |||||
| Title: | Chief Executive Officer | |||||
